210 related articles for article (PubMed ID: 24876617)
1. A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes.
Ramkissoon CM; Aufderheide B; Bequette BW; Palerm CC
J Diabetes Sci Technol; 2014 May; 8(3):529-42. PubMed ID: 24876617
[TBL] [Abstract][Full Text] [Related]
2. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
[TBL] [Abstract][Full Text] [Related]
3. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
Riddle MC; Nahra R; Han J; Castle J; Hanavan K; Hompesch M; Huffman D; Strange P; Öhman P
Diabetes Care; 2018 Nov; 41(11):2346-2352. PubMed ID: 30213882
[TBL] [Abstract][Full Text] [Related]
4. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR
Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651
[TBL] [Abstract][Full Text] [Related]
5. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
Kolterman OG; Schwartz S; Corder C; Levy B; Klaff L; Peterson J; Gottlieb A
Diabetologia; 1996 Apr; 39(4):492-9. PubMed ID: 8778001
[TBL] [Abstract][Full Text] [Related]
6. A model of subcutaneous pramlintide pharmacokinetics and its effect on gastric emptying: Proof-of-concept based on populational data.
Furió-Novejarque C; Sala-Mira I; Díez JL; Bondia J
Comput Methods Programs Biomed; 2024 Feb; 244():107968. PubMed ID: 38064957
[TBL] [Abstract][Full Text] [Related]
7. ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes.
Andersen G; Meiffren G; Famulla S; Heise T; Ranson A; Seroussi C; Eloy R; Gaudier M; Charvet R; Chan YP; Soula O; DeVries JH
Diabetes Obes Metab; 2021 Apr; 23(4):961-970. PubMed ID: 33336850
[TBL] [Abstract][Full Text] [Related]
8. In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes.
Micheletto F; Dalla Man C; Kolterman O; Chiquette E; Herrmann K; Schirra J; Kovatchev B; Cobelli C
Diabetes Technol Ther; 2013 Oct; 15(10):802-9. PubMed ID: 23865841
[TBL] [Abstract][Full Text] [Related]
9. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
Fineman MS; Koda JE; Shen LZ; Strobel SA; Maggs DG; Weyer C; Kolterman OG
Metabolism; 2002 May; 51(5):636-41. PubMed ID: 11979398
[TBL] [Abstract][Full Text] [Related]
10. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
Singh-Franco D; Robles G; Gazze D
Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
[TBL] [Abstract][Full Text] [Related]
11. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.
Chase HP; Lutz K; Pencek R; Zhang B; Porter L
J Pediatr; 2009 Sep; 155(3):369-73. PubMed ID: 19464026
[TBL] [Abstract][Full Text] [Related]
12. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
[TBL] [Abstract][Full Text] [Related]
13. Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes.
Wendt SL; Ranjan A; Møller JK; Schmidt S; Knudsen CB; Holst JJ; Madsbad S; Madsen H; Nørgaard K; Jørgensen JB
J Diabetes Sci Technol; 2017 Nov; 11(6):1101-1111. PubMed ID: 28654314
[TBL] [Abstract][Full Text] [Related]
14. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
[TBL] [Abstract][Full Text] [Related]
15. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.
Herrmann K; Frias JP; Edelman SV; Lutz K; Shan K; Chen S; Maggs D; Kolterman OG
Postgrad Med; 2013 May; 125(3):136-44. PubMed ID: 23748514
[TBL] [Abstract][Full Text] [Related]
16. Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes.
Fang J; Landersdorfer CB; Cirincione B; Jusko WJ
AAPS J; 2013 Jan; 15(1):15-29. PubMed ID: 23054970
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion.
McVey E; Hirsch L; Sutter DE; Kapitza C; Dellweg S; Clair J; Rebrin K; Judge K; Pettis RJ
J Diabetes Sci Technol; 2012 Jul; 6(4):743-54. PubMed ID: 22920798
[TBL] [Abstract][Full Text] [Related]
18. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.
Heptulla RA; Rodriguez LM; Bomgaars L; Haymond MW
Diabetes; 2005 Apr; 54(4):1100-7. PubMed ID: 15793249
[TBL] [Abstract][Full Text] [Related]
19. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.
Nyholm B; Orskov L; Hove KY; Gravholt CH; Møller N; Alberti KG; Moyses C; Kolterman O; Schmitz O
Metabolism; 1999 Jul; 48(7):935-41. PubMed ID: 10421239
[TBL] [Abstract][Full Text] [Related]
20. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.
Weinzimer SA; Sherr JL; Cengiz E; Kim G; Ruiz JL; Carria L; Voskanyan G; Roy A; Tamborlane WV
Diabetes Care; 2012 Oct; 35(10):1994-9. PubMed ID: 22815298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]